UKGulf Trade Deal Hailed as Monumental Achievement by Bahrain Minister
NFL Seeks Ban on Certain Sports Prediction Contracts Including GameSpecific Bets and Injury Markets
Luhansk Strike Escalates Tensions Potential Economic Repercussions as Russia Vows Retaliation
London Stock Exchange Group Reports Income Growth Driven by Tradeweb Platform
SiTime Corporation SITM Plans 12 Billion Convertible Notes Offering to Fund Renesas Timing Business Acquisition
Inflation Squeeze Travel Recreation and Food Prices Surge Ahead of Memorial Day Weekend
ALMS Q1 2026 Earnings EPS Beat Partially Offsets Investor Concerns
NVST Q1 2026 Earnings EPS Beats Estimates Despite Stock Decline
TG Therapeutics Q1 2026 Earnings EPS Disappoints as Stock Declines
Ainos Inc AIMD Q1 2025 Earnings Breakthrough Pipeline Progress Drives Massive Stock Surge Despite No Revenue
Integra Resources Corp Q1 2026 Earnings EPS Miss Amid PreRevenue Development Stage
WKHS Q1 2026 Earnings Deepening Losses Amid Operational Transition
Park Hotels Resorts PK Rallies 3 Support Holds Resistance in Sight
Tianci International Inc CIIT Holds Steady Near Support Level as Trading Activity Remains Light
Caesarstone Shares Slide Over 7 Key Levels Under Pressure
Micron Technology MU Slips 146 as Bullish Momentum Fades Near 750
Donegal Group Inc DGICB Holds Steady at 1829 Amid Quiet Trading
BSE NSE to Remain Closed on Bakri Id Stock Market Holiday on May 28 2026
NU Q1 2026 Earnings EPS Misses Expectations Despite Positive Stock Reaction
Pelthos Therapeutics Inc PTHS Declines 263 as Stock Tests Key Support Levels
Castle Biosciences CSTL Faces Pullback Amid Market Volatility Key Levels in Focus
Centurion Acquisition Corp ALF SPAC Holds Steady Near 1088 Amid Minimal Movement
ADTRAN Holdings Inc ADTN Edges Higher as Shares Approach Key Resistance Level
AMN Healthcare Services AMN Rallies 268 Approaches Resistance at 2933
STERIS STE Faces Modest Pullback as Shares Test Key Technical Zone
Renasant Corporation RNST Holds Near Key Support as Modest Gains Signal Stabilization
Crinetics Pharmaceuticals CRNX Slips 152 as Biotech Sentiment Remains Cautious